The regenerative medicine (RM) industry deals with regrowing, repairing, or replacing cells, tissues, or organs. RM treatments are mostly applied in oncology, orthopedics, and dermatology to treat bone injuries, bone decay, burns, and skin damage. However, usage in cardiovascular and neuro-related diseases is also increasing, as more treatments receive regulatory approval. RM targets the root cause of a disease, providing potential cures rather than just addressing symptoms like most other common treatments (e.g., drugs and surgeries).
There are three main types of RM: cell therapy, gene therapy, and tissue engineering. Cell therapy, the most common type, introduces a cell into a patient's body to repair or replace damaged cells. Meanwhile, gene therapy modifies or introduces new genes into the body to treat the disease, while tissue engineering replaces or builds new tissues around damaged organs; these are, however, yet to gain prominence in the RM market.
Note: Currently, we do not actively cover this industry, but we have identified it as a potential industry to cover.
Catalent is a listed company that collaborates with pharmaceutical companies, biotech companies and other stakeholders in the pharmaceutical industry in order to enable drug delivery, development and supply management. The company specializes in the manufacturing of softgel products, which is a method of oral drug delivery for patients, and inhalation products. Catalent also provides customized clinical supply management services for smaller pharmaceutical companies. The company has a global presence with service centers, research and production facilities in Europe and Asia in addition to the Americas.
R&D Cell Therapy:
R&D Gene Therapy:
Tissue Engineering Therapies:
No investor data is available